Today: 7 February 2026
Subscribe
Browse Category

Clinical Trials News 8 December 2025 - 20 December 2025

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals Stock (RXRX) News and Forecasts for Dec. 20, 2025: TUPELO Trial Data, JPMorgan Upgrade, and What Comes Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) heads into the weekend of December 20, 2025 with investors still digesting a fast-moving sequence of catalysts: fresh clinical data for its lead program REC-4881, a notable JPMorgan upgrade, and a burst of unusually heavy trading volume that has kept the stock in the spotlight. Because U.S. markets are closed on Saturday, the most recent trading reference is Friday’s close (Dec. 19, 2025). RXRX last traded around $4.26 after a volatile week that included a one-day surge and a quick pullback. StockAnalysis RXRX stock price action this week: the “upgrade pop” meets reality checks RXRX’s
20 December 2025
·····
Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

Edgewise Therapeutics Stock (EWTX) Today: Why Shares Fell on Dec. 18, 2025, Plus Latest News, Analyst Forecasts, and Key Clinical Catalysts

December 18, 2025 — Edgewise Therapeutics, Inc. (NASDAQ: EWTX) saw its shares slide sharply in Thursday trading, a reminder that clinical-stage biotech stocks can move fast even when there’s no single headline screaming for attention. EWTX finished the session around $20.35, down roughly 8.8% from the prior close, after trading between about $20.33 and $22.81. StockAnalysis That drop matters because the Edgewise story is still mostly about future clinical readouts and regulatory path clarity, not current product revenue. The company is advancing late-stage work in muscular dystrophies (with its lead program, sevasemten) and also developing cardiac sarcomere modulators for conditions
18 December 2025
·····
Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals (RXRX) Stock News & Forecast (Dec. 18, 2025): JPMorgan Upgrade, REC-4881 Trial Momentum, and What Analysts See Next

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is back in the market’s spotlight on December 18, 2025, after a sharp move higher driven by fresh Wall Street optimism and a growing pile of real-world “proof points” for the company’s AI-driven drug discovery thesis. The setup is classic biotech: a clinical readout starts the spark, an analyst upgrade adds oxygen, and the stock begins to trade more on “what this could become” than “what this is today.” On the tape, RXRX has recently traded around $4.68 with a market cap near $2.1 billion, following a double-digit percentage jump in the prior session. Investing.com
18 December 2025
·····
Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025

December 18, 2025 — Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) is back on traders’ radar after the company reported fresh clinical observations from its Phase 2 breast cancer program and implemented another reverse stock split to consolidate shares. The result: a whiplash week for the stock, a surge in attention, and a new set of near-term catalysts that now matter more than anything else. Below is a detailed breakdown of the latest PCSA news, forecasts, and analysis circulating as of Dec. 18, 2025—and why the next clinical checkpoint in early 2026 is the real plot twist investors will be waiting for.
18 December 2025
····
Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

Immunome (IMNM) Stock Surges After Positive Phase 3 Varegacestat Data: Latest News, Analyst Forecasts, and What Comes Next (Dec. 15, 2025)

December 15, 2025 — Immunome, Inc. (NASDAQ: IMNM) is having the kind of biotech day that traders circle in red ink: a major clinical trial win, a sharp move in the share price, and a fast-rising debate over what “best-in-class” might be worth if regulators agree. The catalyst is Immunome’s positive topline Phase 3 RINGSIDE results for varegacestat (formerly AL102) in progressing desmoid tumors—a rare, non-metastatic but often aggressive disease that can cause severe pain and disability. Reuters reported the news pushed the stock up 34.3% in premarket trading Monday. Reuters By mid-session, IMNM remained strongly higher. As of 14:46
15 December 2025
·····
Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute (RZLT) Stock Update Dec. 12, 2025: Phase 3 sunRIZE Miss Sparks Selloff, Analysts Reset Targets, and 2026 Catalysts

Rezolute, Inc. (NASDAQ: RZLT) is one of the most closely watched biotech movers heading into the Dec. 12, 2025 session after a pivotal clinical trial miss triggered a historic repricing of the stock. As of the latest available trading update on Friday, December 12, 2025, Rezolute shares are trading around $1.40, down roughly $9.55 versus the prior close—about an 87% one-day collapse that has reset expectations across Wall Street. This article covers what happened, why it matters, where sell-side forecasts now stand (as of 12/12/2025), and what catalysts could still move Rezolute stock next. What happened to Rezolute stock: the
12 December 2025
····
Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio (NASDAQ: BLTE) Stock: DRAGON Trial Breakthrough, $350 Million Offering and Outlook After a 130% Rally

Belite Bio, Inc. (NASDAQ: BLTE) has turned into one of 2025’s most closely watched biotech stories. On the back of a pivotal Phase 3 win in Stargardt disease and a large equity raise, the small-cap ophthalmology specialist has seen its share price more than double this year and its market value climb into the multi‑billion‑dollar range.BioPharma Dive+1 As of the afternoon of December 11, 2025, Belite Bio stock is trading around $154 per share, up roughly 4–5% on the day and more than 130% year‑to‑date, giving the company a market capitalization of roughly $5–6 billion.Stock Titan+1 The rally has pushed
11 December 2025
·····
Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals plc (NASDAQ: BDRX) has turned into one of the most volatile biotech tickers of late 2025. After a sharp multi‑day surge driven by retail trading interest and momentum headlines, the stock has whipsawed back down, even as the company advances a pivotal Phase 3 trial in a rare inherited cancer syndrome and lines up multiple new financing options. StockInvest+2MarketWatch+2 This article looks at where BDRX stock stands on December 10, 2025, the latest clinical and regulatory news from Biodexa, the company’s increasingly complex capital structure, and how third‑party models and analysts are framing the risk–reward profile into 2026.
10 December 2025
·····
Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

As of December 9, 2025 Exicure, Inc. (NASDAQ: XCUR) has suddenly moved from obscure micro‑cap to front‑page biotech story. After the company reported positive topline Phase 2 data for its lead drug candidate burixafor in multiple myeloma at the 2025 ASH Annual Meeting on December 8, the stock exploded higher in after‑hours and pre‑market trading.Exicure+2Investing.com+2 Below is a comprehensive look at the latest trial results, recent financials, analyst and algorithmic forecasts, and the key risks around Exicure stock as of December 9, 2025. Exicure (XCUR) Stock Today: Price, Volume and Recent Performance Exicure shares have been extraordinarily volatile going into
9 December 2025
·····
Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced it had dosed the first subjects in its Alzheimer’s disease trial ARO‑MAPT and highlighted a string of recent FDA victories and deal-driven cash inflows. Arrowhead Pharmaceuticals, Inc.+2MarketBeat+2 The rally caps a stunning year in which Arrowhead stock has delivered a year‑to‑date return of roughly 270% and a one‑year gain in the 160–200% range, depending on the data provider, vastly outpacing
8 December 2025
····
Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood cancers at the American Society of Hematology (ASH) Annual Meeting and scheduled a corporate webcast for this evening. MarketBeat+3GlobeNewswire+3GlobeNewswire+3 The rally comes barely two months after Nurix posted a weak third quarter and executed a large equity raise, underscoring how heavily sentiment in this name is tied to the clinical trajectory of its degrader pipeline. ChartMill+2StockAnalysis+2 NRIX stock today: price
8 December 2025
·····
Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals’ stock is back in the spotlight on 8 December 2025 after the company reported encouraging mid‑stage trial results for its AI‑discovered drug REC‑4881 in a rare, cancer‑linked condition called familial adenomatous polyposis (FAP). The news gives investors something they’ve been waiting on for years: early clinical proof that Recursion’s AI‑driven platform might actually work in real patients. GlobeNewswire+1 Shares of Recursion (ticker: RXRX) traded in the mid‑$4 range on Monday, up low single digits intraday after jumping as much as around 6% in pre‑market trading on the back of the data, according to Reuters and Benzinga. Reuters+1 Below
8 December 2025
·····
1 … 3 4 5 6 7 … 9

Stock Market Today

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

Cummins (CMI) stock price rebounds after earnings whipsaw as investors eye data-center power demand

7 February 2026
Cummins shares jumped 6.8% to $577.73 Friday, recovering from a nearly 9% post-earnings drop the day before. The company reported Q4 revenue up 1% to $8.54 billion, took a $218 million charge tied to its hydrogen business, and guided for 2026 EBITDA of 17–18% of sales. Demand for data center generators offset weakness in North American truck markets. Analyst reaction was mixed; Truist raised its price target.
Corning stock hits first record close since 2000 as jobs, CPI data loom

Corning stock hits first record close since 2000 as jobs, CPI data loom

7 February 2026
Corning shares surged 8.3% to $122.16 Friday, their highest close since the dot-com era, after Meta agreed to buy up to $6 billion in fiber-optic cables. The stock is up 40% since late 2025, fueled by strong first-quarter guidance and AI data-center demand. Insiders sold shares following the rally, SEC filings show. Investors await next week’s U.S. jobs and inflation data for rate signals.
Go toTop